Bibliographic information
GuidelineTherapeutics and COVID-19. Living guideline. 7 December 2021
Year of Publication2021
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
For patients with severe or critical COVID-19. The World Health Organisation (WHO) suggests treatment with casirivimab and imdevimab, under the condition that the patient has seronegative status. Remark: Treatment with casirivimab and imdevimab is in addition to the current standard of care, which includes corticosteroids and IL-6 receptor blockers.
Recommended in favor
Conditional
Certainty of evidence
Low
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Therapeutics and COVID-19: living guideline, 24 September 2021.
Year2021
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, 14 January 2022.
Year2022
InstitutionWorld Health Organization